Eloralintide peptide: weight loss results, Phase 3 trials, and FDA status.
Also searched as LY3841136 · eloralintide peptide · selective amylin receptor agonist
Eloralintide, also known as LY3841136, is Lilly's investigational once-weekly single-peptide selective amylin receptor agonist for obesity and related conditions. A peer-reviewed 48-week Phase 2 trial reported dose-dependent weight reduction, while five recruiting ENLIGHTEN Phase 3 records study obesity, type 2 diabetes, obstructive sleep apnea, knee osteoarthritis, and persistent obesity during weekly incretin treatment. Eloralintide is not a GLP-1 or glucagon receptor agonist, and none of these milestones creates an approved product.
Is Eloralintide approved or available?
No. Eloralintide is an investigational Lilly peptide, not an FDA-approved retail medicine. A completed Phase 2 study and recruiting Phase 3 ENLIGHTEN records establish a clinical program, not a pharmacy product, price, dosing instruction, or authenticated online seller.
Compare Eloralintide with Retatrutide, without losing the country context.
Put evidence status, ClinicalTrials.gov coverage, official United States records, and qualified US research prices in one view. Blank fields stay blank when the underlying dataset does not support a number.
Investigational clinical program
Official product and seller records attached
Investigational clinical program
Five trials, five different research questions.
Every card opens the current ClinicalTrials.gov record. Enrollment and completion dates are sponsor estimates, and an overall Recruiting label does not mean every listed site is accepting participants.
- Phase 3 records
- 5
- Estimated enrollment
- 5,615
- Recruiting site observations
- 479
- Countries listed
- 22
- NCT record
- NCT07321886
- Estimated enrollment
- 1,980
- Primary completion
- Mar 2028
- Recruiting footprint
- 107 sites in 11 countries
- NCT record
- NCT07282600
- Estimated enrollment
- 1,035
- Primary completion
- Jan 2028
- Recruiting footprint
- 104 sites in 8 countries
- NCT record
- NCT07369011
- Estimated enrollment
- 800
- Primary completion
- Mar 2028
- Recruiting footprint
- 65 sites in 8 countries
- NCT record
- NCT07353931
- Estimated enrollment
- 900
- Primary completion
- Mar 2028
- Recruiting footprint
- 95 sites in 11 countries
- NCT record
- NCT07392190
- Estimated enrollment
- 900
- Primary completion
- Jun 2028
- Recruiting footprint
- 108 sites in 9 countries
The 20% figure came from two dose strategies under the efficacy estimand in one trial without type 2 diabetes.
Recruiting records describe planned research. They do not establish future efficacy, safety, approval, price, or public availability.
What can you conclude about Eloralintide today?
These are dated program facts, not a cross-trial ranking, approval forecast, personal treatment recommendation, or proof that a same-name online product is the sponsor's medicine.
Peer-reviewed Phase 2 reporting describes eloralintide as one peptide with amylin receptor agonist activity; LY3841136 is its Lilly code.
Mean efficacy-estimand change in the 9 mg and 6-to-9 mg groups versus 0.4% with placebo.
Completed randomized trial in adults without type 2 diabetes across 46 US research centers.
ENLIGHTEN-1, -2, -3, -4, and -6 study distinct obesity-related populations and outcomes.
Open the record behind each status.
A trial result, country approval, and US approval status answer different questions.
Know which molecule the result belongs to.
- Sponsor
- Eli Lilly and Company
- Mechanism
- Selective amylin 1 receptor agonist
- Route being studied
- Once-weekly subcutaneous injection
- Current stage
- Phase 3 ENLIGHTEN program recruiting
- Featured trial anchors
- NCT06230523 · NCT07321886 · NCT07282600 · NCT07369011 · NCT07353931 · NCT07392190 · NCT05295940
- Evidence checked
- July 22, 2026
Eloralintide weight-loss results, with the trial attached.
This visual shows one selected result, not every dose or endpoint in the program. The percentage remains attached to its duration, population, comparator, analysis method, and source.
Evidence checked July 21, 2026Eloralintide reported 20% mean reduction at 48 weeks under the efficacy estimand, rounded result for two dose strategies. The comparator recorded 0.4% mean reduction.
Bar lengths share a 0 to 30% visual scale. They describe this selected record and do not make separate trials head-to-head.
- Population
- Adults with obesity or overweight and at least one complication
- Participants
- 263 Total randomized trial population
- Dose
- 9 mg and 6-to-9 mg strategies
- Primary analysis
- Efficacy estimand, rounded result for two dose strategies
- Regulatory status
- Investigational; not FDA approved
Eloralintide clinical trials by status, phase, and location.
The current exact-intervention snapshot matches 19 unique NCT records. This chart describes registry coverage and current study fields. It does not compare efficacy, safety, approval probability, eligibility, or treatment access.
Snapshot 2026-07-24Counts use individual locations currently marked Recruiting, not every facility listed on an overall-recruiting study. Repeated centers across studies remain repeated site observations.
Eloralintide vs Retatrutide.
Compare two investigational Lilly peptides by molecular identity, receptor mechanism, study phase, trial result, and current FDA status. No head-to-head result exists, so the page keeps every percentage attached to its own protocol.
Open the Eloralintide vs Retatrutide comparison →Eloralintide across 42 countries.
This profile establishes the program identity and its cited clinical or regulatory record. It does not turn a same-name seller listing into the sponsor’s asset or prove authorization, availability, or lawful supply in another destination.
Compare Eloralintide by country →Compare Eloralintide by US state →Browse the global peptide country dataset →Is Eloralintide approved or available in your country?
Start with the United States FDA record, then check the destination that matters to you. Each country page separates drug identity, authorization, product records, seller claims, and supply rules. Directory checked July 20, 2026.
What the record shows - and what it doesn’t.
Trial percentages are kept beside the design details that make them interpretable. Unknowns stay visible instead of being filled with launch speculation.
The 48-week Phase 2 result is peer reviewed
The Lancet publication reports mean body-weight changes of 9% to 20% across six eloralintide dose and escalation groups at week 48 under the efficacy estimand, compared with 0.4% in the placebo group. The 9 mg and 6-to-9 mg groups each reached a rounded 20% mean change. Those group estimates do not predict an individual's response or establish superiority over another drug.
Selectivity distinguishes the mechanism
Published discovery work describes eloralintide as preferentially activating the human amylin 1 receptor over the calcitonin and amylin 3 receptors. This is different from a GLP-1, GIP, or glucagon receptor agonist. Preclinical comparisons with cagrilintide can explain receptor design, but animal findings cannot establish a human efficacy or tolerability winner.
The ENLIGHTEN program is recruiting
ENLIGHTEN-1 lists 1,980 estimated participants without type 2 diabetes and ENLIGHTEN-2 lists 1,035 with type 2 diabetes. Separate Phase 3 protocols study obstructive sleep apnea, knee osteoarthritis, and persistent obesity during ongoing weekly incretin treatment. The five recruiting records show actual starts from December 2025 through February 2026, with primary completion estimates in 2028 rather than available Phase 3 outcomes.
Phase 3 outcomes are not available
Recruiting records show that the pivotal program is underway, not that efficacy, safety, tolerability, durability, or benefit-risk outcomes have been demonstrated in those populations. Enrollment and completion estimates can change as trial records are updated.
No approved label or commercial route
Eloralintide has no FDA-approved indication, final dose, prescribing information, retail price, pharmacy channel, or insurance policy. An online listing using eloralintide or LY3841136 does not become Lilly clinical material because it shares an investigational name.
Cross-trial rankings remain unsupported
The rounded 20% Phase 2 result cannot be fairly ranked against another program without matching the randomized population, duration, dose, escalation, estimand, placebo response, missing-data method, adherence assumptions, and adverse-event reporting.
The questions behind the search.
Concise answers based on the dated sponsor and trial records below. This is educational reporting, not medical advice.
Is eloralintide a peptide?
Yes. The peer-reviewed Phase 2 report describes eloralintide as a single peptide with amylin receptor agonist activity. It is a long-acting amylin analogue developed for once-weekly subcutaneous administration. Its peptide identity does not make it a GLP-1 drug, a glucagon agonist, an approved medicine, or an authenticated online product. Eloralintide preferentially activates the amylin 1 receptor, while retatrutide uses a different peptide design targeting GIP, GLP-1, and glucagon receptors.
What is eloralintide, and is it the same as LY3841136?
Yes. Eloralintide is the current nonproprietary name for the investigational Lilly molecule previously identified as LY3841136. It is a long-acting amylin analogue designed to preferentially activate the amylin 1 receptor and is being studied as a once-weekly subcutaneous injection. It is not a GLP-1 and glucagon dual agonist, despite some online pages describing it that way. Matching the name and sponsor code resolves the clinical evidence trail; it does not identify an approved medicine, an authentic retail vial, or a dosing instruction for consumers.
What did the eloralintide Phase 2 trial show?
The completed Phase 2 study randomized 263 adults with obesity or overweight and at least one weight-related condition, without type 2 diabetes, to placebo or six eloralintide dose strategies for 48 weeks. The peer-reviewed report found mean efficacy-estimand weight changes ranging from 9% to 20% across eloralintide groups, with rounded 20% changes in the 9 mg and 6-to-9 mg groups versus 0.4% with placebo. Nausea and fatigue were the most common adverse events, with rates varying materially by dose group. The study was not a head-to-head comparison with cagrilintide, retatrutide, tirzepatide, or another program.
Is eloralintide in Phase 3 or available to buy?
Eloralintide is in a recruiting Phase 3 program. ENLIGHTEN-1 studies obesity or overweight without type 2 diabetes, ENLIGHTEN-2 includes type 2 diabetes, ENLIGHTEN-3 studies moderate-to-severe obstructive sleep apnea, ENLIGHTEN-4 studies knee osteoarthritis pain, and ENLIGHTEN-6 studies persistent obesity during weekly incretin treatment. Their current records estimate primary completion in 2028 and do not yet report Phase 3 outcomes. Eloralintide is not FDA approved and has no legitimate approved retail product, label, pharmacy price, or routine prescribing route. Recruiting status must not be interpreted as approval or proof that an online product is authentic Lilly material.
Do not use an investigational name, trial dose, or online research listing as a substitute for approved care. This page does not recommend treatment, sourcing, or participation in a clinical trial.
Understand the product-category boundary →